Top

Published in:

Open Access 01-05-2020 | Parkinson's Disease | Neurology and Preclinical Neurological Studies - Review Article

Neuroprotection in Parkinson’s disease: facts and hopes

Authors: András Salamon, Dénes Zádori, László Szpisjak, Péter Klivényi, László Vécsei

Published in: Journal of Neural Transmission | Issue 5/2020

Abstract

Parkinson’s disease (PD) is the second most common neurodegenerative disease worldwide. Behind the symptoms there is a complex pathological mechanism which leads to a dopaminergic cell loss in the substantia nigra pars compacta. Despite the strong efforts, curative treatment has not been found yet. To prevent a further cell death, numerous molecules were tested in terms of neuroprotection in preclinical (in vitro, in vivo) and in clinical studies as well. The aim of this review article is to summarize our knowledge about the extensively tested neuroprotective agents (Search period: 1991–2019). We detail the underlying pathological mechanism and summarize the most important results of the completed animal and clinical trials. Although many positive results have been reported in the literature, there is still no evidence that any of them should be used in clinical practice (Cochrane analysis was performed). Therefore, further studies are needed to better understand the pathomechanism of PD and to find the optimal neuroprotective agent(s).

Allain H, Bentué-Ferrer D, Akwa Y (2008) Disease-modifying drugs and Parkinson’s disease. Prog Neurobiol 84:25–39. https://doi.org/10.1016/j.pneurobio.2007.10.003 CrossRefPubMed

Ascherio A, Zhang SM, Hernan MA et al (2001) Prospective study of caffeine consumption and risk of Parkinson’s disease in men and women. Ann Neurol 50:56–63CrossRefPubMed

Ascherio A, LeWitt PA, Xu K et al (2009) Urate as a predictor of the rate of clinical decline in Parkinson disease. Arch Neurol 66:1460–1468. https://doi.org/10.1001/archneurol.2009.247 CrossRefPubMedPubMedCentral

Bara-Jimenez W, Sherzai A, Dimitrova T et al (2003) Adenosine A(2A) receptor antagonist treatment of Parkinson’s disease. Neurology 61:293–296. https://doi.org/10.1212/01.wnl.0000073136.00548.d4 CrossRefPubMed

Barhwal K, Hota SK, Baitharu I et al (2009) Isradipine antagonizes hypobaric hypoxia induced CA1 damage and memory impairment: complementary roles of L-type calcium channel and NMDA receptors. Neurobiol Dis 34:230–244CrossRefPubMed

Bartus RT, Baumann TL, Siffert J et al (2013) Safety/feasibility of targeting the substantia nigra with AAV2-neurturin in Parkinson patients. Neurology 80:1698–1701. https://doi.org/10.1212/WNL.0b013e3182904faa CrossRefPubMedPubMedCentral

Bender A, Koch W, Elstner M et al (2006) Creatine supplementation in Parkinson disease: a placebo-controlled randomized pilot trial. Neurology 67:1262–1264. https://doi.org/10.1212/01.wnl.0000238518.34389.12 CrossRefPubMed

Bohár Z, Toldi J, Fülöp F et al (2015) Changing the face of kynurenines and neurotoxicity: therapeutic considerations. Int J Mol Sci 16:9772–9793. https://doi.org/10.3390/ijms16059772 CrossRefPubMedPubMedCentral

Bonini NM, Giasson BI (2005) Snaring the function of alpha-synuclein. Cell 123:359–361. https://doi.org/10.1016/j.cell.2005.10.017 CrossRefPubMed

Bove J, Prou D, Perier C et al (2005) Toxin-induced models of Parkinson’s disease. NeuroRx 2:484–494. https://doi.org/10.1602/neurorx.2.3.484 CrossRefPubMedPubMedCentral

Chen JF, Xu K, Petzer JP et al (2001) Neuroprotection by caffeine and A(2A) adenosine receptor inactivation in a model of Parkinson’s disease. J Neurosci 21:RC143. https://doi.org/10.1523/JNEUROSCI.21-10-j0001.2001 CrossRefPubMedPubMedCentral

Cheng HC, Ulane CM, Burke RE (2010) Clinical progression in Parkinson disease and the neurobiology of axons. Ann Neurol 67:715–725. https://doi.org/10.1002/ana.21995 CrossRefPubMedPubMedCentral

Chung KK, Dawson VL, Dawson TM (2001) The role of the ubiquitin-proteasomal pathway in Parkinson’s disease and other neurodegenerative disorders. Trends Neurosci 24:S7–S14. https://doi.org/10.1016/s0166-2236(00)01998-6 CrossRefPubMed

Cutler DL, Tendolkar A, Grachev ID (2012) Safety, tolerability and pharmacokinetics after single and multiple doses of preladenant (SCH420814) administered in healthy subjects. J Clin Pharm Ther 37:578–587. https://doi.org/10.1111/j.1365-2710.2012.01349.x CrossRefPubMed

De Lau LM, Koudstaal PJ, Hofman A et al (2005) Serum uric acid levels and the risk of Parkinson disease. Ann Neurol 58:797–800. https://doi.org/10.1002/ana.20663 CrossRefPubMed

Djaldetti R, Melamed E (2002) New drugs in the future treatment of Parkinson’s disease. J Neurol 249(Suppl 2):II30–II35. https://doi.org/10.1007/s00415-002-1206-2 CrossRefPubMed

Domanskyi A, Saarma M, Airavaara M (2015) Prospects of neurotrophic factors for Parkinson’s disease: comparison of protein and gene therapy. Hum Gene Ther 26:550–559. https://doi.org/10.1089/hum.2015.065 CrossRefPubMed

Duan W, Ladenheim B, Cutler RG et al (2002) Dietary folate deficiency and elevated homocysteine levels endanger dopaminergic neurons in models of Parkinson’s disease. J Neurochem 80:101–110. https://doi.org/10.1046/j.0022-3042.2001.00676.x CrossRefPubMed

Dusek P, Schneider SA, Aaseth J (2016) Iron chelation in the treatment of neurodegenerative diseases. J Trace Elem Med Biol 38:81–92. https://doi.org/10.1016/j.jtemb.2016.03.010 CrossRefPubMed

Erdö SL, Schäfer M (1991) Memantine is highly potent in protecting cortical cultures against excitotoxic cell death evoked by glutamate and N-methyl-D-aspartate. Eur J Pharmacol 198:215–217. https://doi.org/10.1016/0014-2999(91)90625-z CrossRefPubMed

Fernández-Valle T, Gabilondo I, Gómez-Esteban JC (2019) New therapeutic approaches to target alpha-synuclein in Parkinson’s disease: The role of immunotherapy. Int Rev Neurobiol 146:281–295. https://doi.org/10.1016/bs.irn.2019.06.014 CrossRefPubMed

Fornai F, Battaglia G, Gesi M et al (2001) Dose-dependent protective effects of apomorphine against methamphetamine-induced nigrostriatal damage. Brain Res 898:27–35. https://doi.org/10.1016/s0006-8993(01)02125-4 CrossRefPubMed

Gerlach M, Ben-Shachar D, Riederer P et al (1994) Altered brain metabolism of iron as a cause of neurodegenerative diseases? J Neurochem 63:793–807. https://doi.org/10.1046/j.1471-4159.1994.63030793.x CrossRefPubMed

Godwin-Austen RB, Lee PN, Marmot MG et al (1982) Smoking and Parkinson’s disease. J Neurol Neurosurg Psychiatry 45:577–581. https://doi.org/10.1136/jnnp.45.7.577 CrossRefPubMedPubMedCentral

Greulich W, Fenger E (1995) Amantadine in Parkinson’s disease: pro and contra. J Neural Transm Suppl 46:415–421PubMed

Grünblatt E, Mandel S, Berkuzki T et al (1999) Apomorphine protects against MPTP-induced neurotoxicity in mice. Mov Disord 14:612–618. https://doi.org/10.1002/1531-8257(199907)14:4%3c612:AID-MDS1010%3e3.0.CO;2-6 CrossRefPubMed

Hall ED, Andrus PK, Oostveen JA et al (1996) Neuroprotective effects of the dopamine D2/D3 agonist pramipexole against postischemic or methamphetamine-induced degeneration of nigrostriatal neurons. Brain Res 742:80–88. https://doi.org/10.1016/s0006-8993(96)00968-7 CrossRefPubMed

Heikkila RE, Manzino L, Cabbat FS et al (1984) Protection against the dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine by monoamine oxidase inhibitors. Nature 311:467–469. https://doi.org/10.1038/311467a0 CrossRefPubMed

Hirsch EC, Jenner P, Przedborski S (2013) Pathogenesis of Parkinson’s disease. Mov Disord 28:24–30. https://doi.org/10.1002/mds.25032 CrossRefPubMed

Iida M, Miyazaki I, Tanaka K et al (1999) Dopamine D2 receptor-mediated antioxidant and neuroprotective effects of ropinirole, a dopamine agonist. Brain Res 838:51–59. https://doi.org/10.1016/s0006-8993(99)01688-1 CrossRefPubMed

Jankovic J, Hunter C (2002) A double-blind, placebo-controlled and longitudinal study of riluzole in early Parkinson’s disease. Parkinsonism Relat Disord 8:271–276CrossRefPubMed

Jankovic J, Goodman I, Safirstein B et al (2018) Safety and tolerability of multiple ascending doses of PRX002/RG7935, an anti-α-synuclein monoclonal antibody, in patients with Parkinson disease: a randomized clinical trial. JAMA Neurol 75:1206–1214. https://doi.org/10.1001/jamaneurol.2018.1487 CrossRefPubMedPubMedCentral

Jellinger KA (2017) Brain monoamine oxidases in human parkinsonian disorders. Brain 140:2262–2264. https://doi.org/10.1093/brain/awx190 CrossRefPubMed

Joghataie MT, Roghani M, Negahdar F et al (2004) Protective effect of caffeine against neurodegeneration in a model of Parkinson’s disease in rat: behavioral and histochemical evidence. Parkinsonism Relat Disord 10:465–468. https://doi.org/10.1016/j.parkreldis.2004.06.004 CrossRefPubMed

Kachroo A, Irizarry MC, Schwarzschild MA (2010) Caffeine protects against combined paraquat and maneb-induced dopaminergic neuron degeneration. Exp Neurol 223:657–661. https://doi.org/10.1016/j.expneurol.2010.02.007 CrossRefPubMedPubMedCentral

Kalia LV, Kalia SK (2015) α-Synuclein and Lewy pathology in Parkinson’s disease. Curr Opin Neurol 28:375–381. https://doi.org/10.1097/WCO.0000000000000215 CrossRefPubMed

Kalia LV, Lang AE (2015) Parkinson’s disease. Lancet 386:896–912. https://doi.org/10.1016/S0140-6736(14)61393-3 CrossRefPubMed

Kalia LV, Kalia SK, Lang AE (2015) Disease-modifying strategies for Parkinson’s disease. Mov Disord 30:1442–1450. https://doi.org/10.1002/mds.26354 CrossRefPubMed

Kim CY, Alcalay RN (2017) Genetic forms of Parkinson’s disease. Semin Neurol 37:135–146. https://doi.org/10.1055/s-0037-1601567 CrossRefPubMed

Klivényi P, Toldi J, Vécsei L (2004) Kynurenines in neurodegenerative disorders: therapeutic consideration. Adv Exp Med Biol 541:169–183. https://doi.org/10.1007/978-1-4419-8969-7_10 CrossRefPubMed

Kondo T, Ito T, Sugita Y (1994) Bromocriptine scavenges methamphetamine-induced hydroxyl radicals and attenuates dopamine depletion in mouse striatum. Ann N Y Acad Sci 738:222–229. https://doi.org/10.1111/j.1749-6632.1994.tb21807.x CrossRefPubMed

Kordower JH, Palfi S, Chen EY et al (1999) Clinicopathological findings following intraventricular glial-derived neurotrophic factor treatment in a patient with Parkinson’s disease. Ann Neurol 46:419–424. https://doi.org/10.1002/1531-8249(199909)46:3%3c419:AID-ANA21%3e3.0.CO;2-Q CrossRefPubMed

Kordower JH, Emborg ME, Bloch J et al (2000) Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson’s disease. Science 290:767–773. https://doi.org/10.1126/science.290.5492.767 CrossRefPubMed

Koutsilieri E, Riederer P (2007) Excitotoxicity and new antiglutamatergic strategies in Parkinson’s disease and Alzheimer’s disease. Parkinsonism Relat Disord 13:S329–S331. https://doi.org/10.1016/S1353-8020(08)70025-7 CrossRefPubMed

Lang AE, Gill S, Patel NK et al (2006) Randomized controlled trial of intraputamenal glial cell line-derived neurotrophic factor infusion in Parkinson disease. Ann Neurol 59:459–466. https://doi.org/10.1002/ana.20737 CrossRefPubMed

Langston JW (2017) The MPTP story. J Parkinsons Dis 7:S11–S19. https://doi.org/10.3233/JPD-179006 CrossRefPubMedPubMedCentral

Larsen JP, Boas J, Erdal JE (1999) Does selegiline modify the progression of early Parkinson’s disease? Results from a five-year study. The Norwegian-Danish Study Group. Eur J Neurol 6:539–547CrossRefPubMed

Lees AJ, Shaw KM, Kohout LJ et al (1977) Deprenyl in Parkinson’s disease. Lancet 2:791–795. https://doi.org/10.1016/s0140-6736(77)90725-5 CrossRefPubMed

Majláth Z, Toldi J, Fülöp F et al (2016a) Excitotoxic mechanisms in non-motor dysfunctions and levodopa- induced dyskinesia in Parkinson’s disease: the role of the interaction between the dopaminergic and the kynurenine system. Curr Med Chem 23:874–883. https://doi.org/10.2174/0929867323666160212121915 CrossRefPubMed

Majláth Z, Török N, Toldi J et al (2016b) Memantine and kynurenic acid: current neuropharmacological aspects. Curr Neuropharmacol 14:200–209. https://doi.org/10.2174/1570159X14666151113123221 CrossRefPubMedPubMedCentral

Mandel S, Grünblatt E, Riederer P et al (2003) Neuroprotective strategies in Parkinson’s disease: an update on progress. CNS Drugs 17:729–762. https://doi.org/10.2165/00023210-200317100-00004 CrossRefPubMed

Marek K, Seibyl J, Shoulson I et al (2002) Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression. JAMA 287:1653–1661. https://doi.org/10.1001/jama.287.13.1653 CrossRef

Matthews RT, Ferrante RJ, Klivenyi P et al (1999) Creatine and cyclocreatine attenuate MPTP neurotoxicity. Exp Neurol 157:142–149. https://doi.org/10.1006/exnr.1999.7049 CrossRefPubMed

Mochizuki H, Imai H, Endo K et al (1994) Iron accumulation in the substantia nigra of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced hemiparkinsonian monkeys. Neurosci Lett 168:251–253. https://doi.org/10.1016/0304-3940(94)90462-6 CrossRefPubMed

Müller T, Büttner T, Gholipour AF et al (2003) Coenzyme Q10 supplementation provides mild symptomatic benefit in patients with Parkinson’s disease. Neurosci Lett 341:201–204. https://doi.org/10.1016/s0304-3940(03)00185-x CrossRefPubMed

NINDS NET-PD Investigators (2006) A randomized, double-blind, futility clinical trial of creatine and minocycline in early Parkinson disease. Neurology 66:664–671. https://doi.org/10.1212/01.wnl.0000201252.57661.e1 CrossRef

Nutt JG, Burchiel KJ, Comella CL et al (2003a) Implanted intracerebroventricular. Glial cell line-derived neurotrophic factor. Randomized, double-blind trial of glial cell line-derived neurotrophic factor (GDNF) in PD. Neurology 6:69–73. https://doi.org/10.1212/WNL.60.1.69 CrossRef

Nutt JG, Burchiel KJ, Comella CL et al (2003b) Randomized, double-blind trial of glial cell line-derived neurotrophic factor (GDNF) in PD. Neurology 60:69–73. https://doi.org/10.1212/wnl.60.1.69 CrossRefPubMed

Obinu MC, Reibaud M, Blanchard V et al (2002) Neuroprotective effect of riluzole in a primate model of Parkinson’s disease: behavioral and histological evidence. Mov Disord 17:13–19CrossRefPubMed

Olanow CW, Jankovic J (2005) Neuroprotective therapy in Parkinson’s disease and motor complications: a search for a pathogenesis-targeted, disease-modifying strategy. Mov Disord 20:S3–S10. https://doi.org/10.1002/mds.20457 CrossRefPubMed

Olanow CW, Hauser RA, Gauger L et al (1995) The effect of deprenyl and levodopa on the progression of signs and symptoms in Parkinson’s disease. Ann Neurol 38:771–777. https://doi.org/10.1002/ana.410380512 CrossRefPubMed

Olanow CW, Rascol O, Hauser R et al (2009) A double-blind, delayed-start trial of rasagiline in Parkinson’s disease. N Engl J Med 361:1268–1278. https://doi.org/10.1056/NEJMoa0809335 CrossRefPubMed

Pålhagen S, Heinonen EH, Hägglund J et al (1998) Selegiline delays the onset of disability in de novo parkinsonian patients. Swedish Parkinson Study Group. Neurology 51:520–525. https://doi.org/10.1212/wnl.51.2.520 CrossRefPubMed

Parkinson Study Group (1989) DATATOP: a multicenter controlled clinical trial in early Parkinson’s disease. Arch Neurol 46:1052–1060. https://doi.org/10.1001/archneur.1989.00520460028009 CrossRef

Parkinson Study Group (1993) Effects of tocopherol and Deprenyl on the progression of disability in early Parkinson’s disease. N Eng J Med 328:176–183. https://doi.org/10.1056/NEJM199301213280305 CrossRef

Parkinson Study Group (2002) A controlled trial of rasagiline in early Parkinson disease: the TEMPO Study. Arch Neurol 59:1937–1943. https://doi.org/10.1001/archneur.59.12.1937 CrossRef

Parkinson Study Group (2005) A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study. Arch Neurol 62:241–248. https://doi.org/10.1001/archneur.62.2.241 CrossRef

Parkinson Study Group (2013) Phase II safety, tolerability, and dose selection study of isradipine as a potential disease-modifying intervention in early Parkinson’s disease (STEADY-PD). Mov Disord 28:1823–1831. https://doi.org/10.1002/mds.25639 CrossRef

Parkinson Study Group SURE-PD Investigators, Schwarzschild MA, Ascherio A et al (2014) Inosine to increase serum and cerebrospinal fluid urate in Parkinson disease: a randomized clinical trial. JAMA Neurol 71:141–150. https://doi.org/10.1001/jamaneurol.2013.5528 CrossRef

Peretz C, Segev H, Rozani V et al (2016) Comparison of selegiline and rasagiline therapies in parkinson disease: a real-life study. Clin Neuropharmacol 39:227–231. https://doi.org/10.1097/WNF.0000000000000167 CrossRefPubMedPubMedCentral

Polymeropoulos MH, Lavedan C, Leroy E et al (1997) Mutation in the alpha-synuclein gene identified in families with Parkinson’s disease. Science 276:2045–2047. https://doi.org/10.1126/science.276.5321.2045 CrossRefPubMed

Prediger RD (2010) Effects of caffeine in Parkinson’s disease: from neuroprotection to the management of motor and non-motor symptoms. J Alzheimers Dis 20:S205–S220. https://doi.org/10.3233/JAD-2010-091459 CrossRefPubMed

Qick M (2004) Smoking, nicotine and Parkinson’s disease. Trends Neurosci 27:561–568. https://doi.org/10.1016/j.tins.2004.06.008 CrossRef

Quik M, Jeyarasasingam G (2000) Nicotinic receptors and Parkinson’s disease. Eur J Pharmacol 393:223–230. https://doi.org/10.1016/s0014-2999(99)00888-2 CrossRefPubMed

Rabey JM, Sagi I, Huberman M et al (2000) Rasagiline mesylate, a new MAO-B inhibitor for the treatment of Parkinson’s disease: a double-blind study as adjunctive therapy to levodopa. Clin Neuropharmacol 23:324–330. https://doi.org/10.1097/00002826-200011000-00005 CrossRefPubMed

Rascol O, Brooks DJ, Melamed E (2005) Rasagiline as an adjunct to levodopa in patients with Parkinson’s disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial. Lancet 365:947–954CrossRefPubMed

Rockenstein E, Ostroff G, Dikengil F et al (2018) Combined active humoral and cellular immunization approaches for the treatment of synucleinopathies. J Neurosci 38:1000–1014. https://doi.org/10.1523/JNEUROSCI.1170-17.2017 CrossRefPubMedPubMedCentral

Rojas P, Altagracia M, Kravsov J et al (1992) Partially protective effect of amantadine in the MPTP model of Parkinson’s disease. Proc West Pharmacol Soc 35:33–35PubMed

Ross GW, Abbott RD, Petrovitch H et al (2000) Association of coffee and caffeine intake with the risk of Parkinson disease. JAMA 283:2674–2679. https://doi.org/10.1001/jama.283.20.2674 CrossRefPubMed

Saaksjarvi K, Knekt P, Rissanen H et al (2008) Prospective study of coffee consumption and risk of Parkinson’s disease. Eur J Clin Nutr 62:908–915. https://doi.org/10.1038/sj.ejcn.1602788 CrossRefPubMed

Sas K, Robotka H, Toldi J et al (2007) Mitochondria, metabolic disturbances, oxidative stress and the kynurenine system, with focus on neurodegenerative disorders. J Neurol Sci 257:221–239. https://doi.org/10.1016/j.jns.2007.01.033 CrossRefPubMed

Schapira AH (2008) Progress in neuroprotection in Parkinson’s disease. Eur J Neurol 15(Suppl 1):5–13. https://doi.org/10.1111/j.1468-1331.2008.02055.x CrossRefPubMed

Schwab RS, Poskanzer DC, England AC et al (1972) Amantadine in Parkinson’s disease: review of more than 2 years’ experience. JAMA 222:792–795. https://doi.org/10.1001/jama.1972.03210070026008 CrossRefPubMed

Seidl SE, Potashkin JA (2011) The promise of neuroprotective agents in Parkinson’s disease. Front Neurol 2:68. https://doi.org/10.3389/fneur.2011.00068 CrossRefPubMedPubMedCentral

Seif el Nasr M, Peruche B, Rossberg C et al (1990) Neuroprotective effect of memantine demonstrated in vivo and in vitro. Eur J Pharmacol 185:19–24. https://doi.org/10.1016/0014-2999(90)90206-l CrossRefPubMed

Shults CW, Oakes D, Kieburtz K et al (2002) Effects of coenzyme Q10 in early Parkinson disease: evidence of slowing of the functional decline. Arch Neurol 59:1541–1550. https://doi.org/10.1001/archneur.59.10.1541 CrossRefPubMed

Sian-Hülsmann J, Mandel S, Youdim MB (2010) The relevance of iron in the pathogenesis of Parkinson’s disease. J Neurochem 118:939–957. https://doi.org/10.1111/j.1471-4159.2010.07132.x CrossRef

Spencer B, Trinh I, Rockenstein E (2019) Systemic peptide mediated delivery of an siRNA targeting α-syn in the CNS ameliorates the neurodegenerative process in a transgenic model of Lewy body disease. Neurobiol Dis 127:163–177. https://doi.org/10.1016/j.nbd.2019.03.001 CrossRefPubMedPubMedCentral

Stern G (1996) Parkinson’s disease. The apoptosis hypothesis. Adv Neurol 69:101–107PubMed

Storch A, Jost WH, Vieregge P et al (2007) Randomized, double-blind, placebo-controlled trial on symptomatic effects of coenzyme Q(10) in Parkinson disease. Arch Neurol 64:938–944. https://doi.org/10.1001/archneur.64.7.nct60005 CrossRefPubMed

Tábi T, Vécsei L, Youdim MB et al (2019) Selegiline: a molecule with innovative potential. J Neural Transm (Vienna). https://doi.org/10.1007/s00702-019-02082-0 CrossRef

Tan EK, Tan C, Fook-Chong SM et al (2003) Dose-dependent protective effect of coffee, tea, and smoking in Parkinson’s disease: a study in ethnic Chinese. J Neurol Sci 216:163–167. https://doi.org/10.1016/j.jns.2003.07.006 CrossRefPubMed

Tarazi FI, Sahli ZT, Wolny M et al (2014) Emerging therapies for Parkinson’s disease: from bench to bedside. Pharmacol Ther. https://doi.org/10.1016/j.pharmthera.2014.05.010 CrossRefPubMed

Teismann P, Tieu K, Choi DK et al (2003) Cyclooxygenase-2 is instrumental in Parkinson’s disease neurodegeneration. Proc Natl Acad Sci 100:5473–5478. https://doi.org/10.1073/pnas.0837397100 CrossRefPubMedPubMedCentral

Tetrud JW, Langston JW (1989) The effect of deprenyl (selegiline) on the natural history of Parkinson’s disease. Science 245:519–522. https://doi.org/10.1126/science.2502843 CrossRefPubMed

The Parkinson Study Group (2004) Levodopa and the progression of Parkinson’s disease. N Engl J Med 351:2498–2508. https://doi.org/10.1056/NEJMoa033447 CrossRef

The Parkinson Study Group QE3 Investigators (2014) A randomized clinical trial of high dosage Coenzyme Q10 in early Parkinson disease: no evidence of benefit. JAMA Neurol 71:543–552. https://doi.org/10.1001/jamaneurol.2014.131 CrossRef

Tong J, Rathitharan G, Meyer JH et al (2017) Brain monoamine oxidase B and A in human parkinsonian dopamine deficiency disorders. Brain 140:2460–2474. https://doi.org/10.1093/brain/awx172 CrossRefPubMedPubMedCentral

Uitti RJ, Rajput AH, Ahlskog JE et al (1996) Amantadine treatment is an independent predictor of improved survival in Parkinson’s disease. Neurology 46:1551–1556. https://doi.org/10.1212/wnl.46.6.1551 CrossRefPubMed

Vécsei L, Szalárdy L, Fülöp F et al (2013) Kynurenines in the CNS: recent advances and new questions. Nat Rev Drug Discov 12:64–82. https://doi.org/10.1038/nrd3793 CrossRefPubMed

Verschuur CVM, Suwijn SR, Boel JA et al (2019) Randomized delayed-start trial of levodopa in Parkinson’s disease. N Engl J Med 380:315–324. https://doi.org/10.1056/NEJMoa1809983 CrossRefPubMed

Visanji NP, Brooks PL, Hazrati L-N et al (2013) The prion hypothesis in Parkinson’s disease: Braak to the future. Acta Neuropathol Commun 1:2. https://doi.org/10.1186/2051-5960-1-2 CrossRefPubMedPubMedCentral

Weinreb O, Amit T, Riederer P et al (2011) Neuroprotective profile of the multitarget drug rasagiline in Parkinson’s disease. Int Rev Neurobiol 100:127–149. https://doi.org/10.1016/B978-0-12-386467-3.00007-8 CrossRefPubMed

Whone AL, Watts RL, Stoessl AJ et al (2003) Slower progression of Parkinson’s disease with ropinirole versus levodopa: The REAL-PET study. Ann Neurol 54:93–101CrossRefPubMed

Youdim MB (2010) Rasagiline in Parkinson’s disease. N Engl J Med 362:657–658. https://doi.org/10.1056/NEJMc0910491 CrossRefPubMed

Youdim MB, Gross A, Finberg JP (2001) Rasagiline [N-propargyl-1R(+)-aminoindan], a selective and potent inhibitor of mitochondrial monoamine oxidase B. Br J Pharmacol 132:500–506. https://doi.org/10.1038/sj.bjp.0703826 CrossRefPubMedPubMedCentral

Zádori D, Klivényi P, Plangár I et al (2011) Endogenous neuroprotection in chronic neurodegenerative disorders: with particular regard to the kynurenines. J Cell Mol Med 15:701–717. https://doi.org/10.1111/j.1582-4934.2010.01237.x CrossRefPubMedPubMedCentral

Zádori D, Klivényi P, Szalárdy L et al (2012a) Mitochondrial disturbances, excitotoxicity, neuroinflammation and kynurenines: novel therapeutic strategies for neurodegenerative disorders. J Neurol Sci 322:187–191. https://doi.org/10.1016/j.jns.2012.06.004 CrossRefPubMed

Zádori D, Klivényi P, Toldi J et al (2012b) Kynurenines in Parkinson’s disease: therapeutic perspectives. J Neural Transm 119:275–283. https://doi.org/10.1007/s00702-011-0697-3 CrossRefPubMed

Zádori D, Szalárdy L, Toldi J et al (2013) Some molecular mechanisms of dopaminergic and glutamatergic dysfunctioning in Parkinson’s disease. J Neural Transm 120:673–681. https://doi.org/10.1007/s00702-012-0930-8 CrossRefPubMed

Zou L, Xu J, Jankovic J et al (2000) Pramipexole inhibits lipid peroxidation and reduces injury in the substantia nigra induced by the dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in C57BL/6 mice. Neurosci Lett 281:167–170. https://doi.org/10.1016/s0304-3940(00)00853-3 CrossRefPubMed

Title: Neuroprotection in Parkinson’s disease: facts and hopes
Authors: András Salamon
Dénes Zádori
László Szpisjak
Péter Klivényi
László Vécsei
Publication date: 01-05-2020
Publisher: Springer Vienna
Keywords: Parkinson's Disease
Levodopa
Rasagiline
Selegiline
Published in: Journal of Neural Transmission / Issue 5/2020
Print ISSN: 0300-9564
Electronic ISSN: 1435-1463
DOI: https://doi.org/10.1007/s00702-019-02115-8

At a glance: The STEP trials

Springer Medicine

Neuroprotection in Parkinson’s disease: facts and hopes

Abstract

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 5/2020

Kinesiology training in patients with Parkinson’s disease: results of a pilot study

Subacute administration of both methcathinone and manganese causes basal ganglia damage in mice resembling that in methcathinone abusers

Agricultural work and reduced circulating uric acid are both associated with initial hospital admission for Parkinson’s disease

Non-pharmacological management of cognitive impairment in Parkinson’s disease

Parkinson’s disease treatment: past, present, and future

A personal note—Gerald Stern and Yves Agid: A walk in Piazza del Popolo in Rome, sometime in 1998